Exposure Matching Using Population Pharmacokinetic Modeling and Simulation to Support Rimegepant Dose Selection for Pediatric Patients With Migraine
Clinical and Translational Science · 2025
DOI: 10.1111/cts.70360 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Craig M Comisar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Certara, Princeton, New Jersey, USA. Hauptthemen laut MEDLINE: Migraine Disorders, Piperidines, Models, Biological, Pyridines. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Rimegepant is a small molecule calcitonin gene‐related peptide receptor antagonist approved as a 75 mg orally disintegrating tablet for the acute treatment of migraine and the prevention of episodic migraine in adults. A population pharmacokinetic model for oral rimegepant was previously developed using data from 11 phase I studies in adults. This analysis updated the population pharmacokinetic model with data from one pediatric (20 participants) and two adult (74 participants) studies. The resultant population pharmacokinetic model was used to predict rimegepant exposure following single or every‐other‐day dosing in a virtual pediatric population generated using United States national growth charts. Exposure with rimegepant 75 mg orally disintegrating tablet was evaluated in simulated participants aged 6 to 17 years (1000 simulations/1‐year age group), and exposure with rimegepant 25, 35, 50, and 75 mg was evaluated in simulated participants weighing 9 to 75 kg (1000 simulations/5 kg increment). Rimegepant doses for pediatric patients were selected using predicted pediatric/adult exposure ratios close to 1 and ≤ 2. The recommended single and every‐other‐day doses of rimegepant orally disintegrating tablet in the pediatric population were 75 mg in adolescents 12 to < 18 years of age and children 6 to < 12 years of age and with a body weight > 40 kg; 50 mg in children 6 to < 12 years of age with a body weight > 25 to ≤ 40 kg; and 35 mg in children 6 to < 12 years of age with a body weight > 15 to ≤ 25 kg. These selected doses will support further evaluation of rimegepant efficacy and safety in pediatric patients with migraine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Certara, Princeton, New Jersey, USA.
- Pfizer Inc., Groton, Connecticut, USA.
- Pfizer Inc., La Jolla, California, USA.
- Pfizer Inc., New York, New York, USA.
- Pfizer Inc., Cambridge, Massachusetts, USA.
ORCID-Profile: Jim H Hughes, Gary Mo, Abhijeet Jakate, Chay Ngee Lim, Jing Liu
Zitieren
APA
Comisar, C. M., Hughes, J. H., Mo, G., Bhardwaj, R., Jakate, A., Lim, C. N., & Liu, J. (2025). Exposure Matching Using Population Pharmacokinetic Modeling and Simulation to Support Rimegepant Dose Selection for Pediatric Patients With Migraine. Clinical and Translational Science. https://doi.org/10.1111/cts.70360
Vancouver
Comisar CM, Hughes JH, Mo G, Bhardwaj R, Jakate A, Lim CN, et al. Exposure Matching Using Population Pharmacokinetic Modeling and Simulation to Support Rimegepant Dose Selection for Pediatric Patients With Migraine. Clinical and Translational Science. 2025. doi:10.1111/cts.70360
BibTeX
@article{Comisar2025,
author = {Comisar, Craig M and Hughes, Jim H and Mo, Gary and Bhardwaj, Rajinder and Jakate, Abhijeet and Lim, Chay Ngee and Liu, Jing},
title = {Exposure Matching Using Population Pharmacokinetic Modeling and Simulation to Support Rimegepant Dose Selection for Pediatric Patients With Migraine},
journal = {Clinical and Translational Science},
year = {2025},
doi = {10.1111/cts.70360}
}
EUVIMED